CClinicalTrials.gg
Sign In
CompletedNCT01722916Updated Jul 1, 2026

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

An Early Phase 1 interventional study of Hyaluronidase in Drug Safety, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Northwestern University · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 7 months ago, and no results have been posted to the registry.
Phase
Early Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

02

Conditions studied

  • Drug Safety
03

In context

Lead sponsor

Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18 and over
  • The subjects are in good health
  • The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Pregnancy or Lactation
  • Subjects who are unable to understand the protocol or to give informed consent
  • Subjects with mental illness
  • Recent Accutane use in the past 6 months
  • Subjects prone to hypertrophic and keloidal scarring
  • Subjects with tattoos and/or scars on upper medial arms (the treatment area)
  • Subjects with known hypersensitivity to hyaluronic acid
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Dose of Hyaluronidase

    Drug: Hyaluronidase

Interventions

  • DrugHyaluronidase
06

What researchers measure

Primary outcomes

  1. Dose of hyaluronidase injected until the filler is no longer detectable

    Time frame: 2 weeks

07

Study locations

1 site
  • Northwestern University Department of Dermatology
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Alam M, Hughart R, Geisler A, Paghdal K, Maisel A, Weil A, West DP, Veledar E, Poon E. Effectiveness of Low Doses of Hyaluronidase to Remove Hyaluronic Acid Filler Nodules: A Randomized Clinical Trial. JAMA Dermatol. 2018 Jul 1;154(7):765-772. doi: 10.1001/jamadermatol.2018.0515. PubMed 29710212 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01722916
Lead sponsor
Northwestern University
Responsible party
Murad Alam (Professor in Dermatology, Otolaryngology- Head and Neck Surgery and Surgery-Organ Transplantation, Northwestern University) — Principal investigator
First posted
Nov 7, 2012
Start date
Oct 2012
Primary completion
Feb 22, 2022
Completion
Feb 22, 2022
Last update
Jul 1, 2026

Study contacts

Murad Alam, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Northwestern University

Start the discussion